TRVI

Trevi Therapeutics' stock has been impacted by several key events in the past six months. The company announced and closed a public offering of common stock, raising approximately $173 million in gross proceeds, extending its cash runway into 2030. Following the public offering announcement, Trevi's shares experienced a surge, reaching an all-time high, but also experienced some volatility after its Q1 2026 earnings call. The company reported its Fourth Quarter and Year End 2025 financial results in March 2026 and its First Quarter 2026 financial results in May 2026, with the Q1 report indicating a net loss of $13.2 million. Trevi Therapeutics completed an End-of-Phase 2 meeting with the FDA and plans to initiate Phase 3 trials for IPF-related chronic cough in 2026, along with Phase 2b trials for non-IPF ILD-related chronic cough and RCC. Trevi Therapeutics has participated in various healthcare conferences and investor events.